All In Biotech

Drug Trial Radar · NCT01347190

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

A Double Blind, Randomized, Placebo Controlled, Single Dose, Phase I Study of the Safety and Tolerability of Alpha1 Proteinase Inhibitor (Human) Inhalation Solution (CR002) in Subjects With Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Apr 2011

Primary completion

Aug 2011

Study completion Aug 2011

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
May 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.

Conditions

  • Cystic Fibrosis

Interventions

  • CR002 Liquid APIBiological

    A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.

  • PlaceboBiological

    A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse eventsTime frame: 44 Days (Day -21 to Day 22)

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Site 11

    Sofia, Bulgaria

  • Site 12

    Varna, Bulgaria

  • Site 30

    Debrecen, Hungary

  • Site 24

    Bialystok, Poland

  • Site 22

    Gdansk, Poland

  • Site 21

    Poznan, Poland

  • Site 20

    Rabka-Zdrój, Poland

  • Site 23

    Warsaw, Poland

  • Site 42

    Papworth Hospital, United Kingdom

  • Site 40

    Penarth, United Kingdom

  • Site 41

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.